Viral Infections

Introduction to Viral Infections

Viral infections, such as HIV, primarily target cells expressing the CD4 receptor, including CD4+ T lymphocytes, monocytes/macrophages, and dendritic cells, leading to immunodeficiency and increased susceptibility to opportunistic infections and malignancies, as noted by the American College of Physicians 1 and 2

Early establishment of viral reservoirs, such as latent infection of resting memory CD4+ T cells, prevents viral eradication 1
Host genetic factors, such as CCR5-Δ32 mutation, HLA alleles, and APOL1 gene variants, affect susceptibility and progression of HIV infection 3

The primary treatment goals for managing viral infections include maximal suppression of viral load, restoration and preservation of immune function, and reduction of virus-related morbidity and mortality, as recommended by the American College of Physicians 1

Viral entry requires binding of viral envelope glycoprotein gp120 to CD4 receptor, subsequent interaction with co-receptors, and fusion of viral and cellular membranes mediated by gp41, ultimately leading to CD4+ T cell depletion 2
CNS infection occurs early in the disease course, with HIV crossing the blood-brain barrier primarily via infected monocytes/macrophages, leading to neurocognitive disorders 2
Intestinal mucosal damage is characterized by massive depletion of gut-associated lymphoid tissue CD4+ T cells, breakdown of intestinal barrier, and microbial translocation driving systemic immune activation 4
CNS pathology includes direct viral infection, inflammatory responses, and neurotoxic viral proteins, leading to a spectrum of neurocognitive disorders 3
Cardiovascular effects are driven by chronic inflammation, immune activation, endothelial injury, and disordered coagulation, increasing cardiovascular risk 5
Renal manifestations include HIV-associated nephropathy, direct infection of renal epithelial cells, and genetic predisposition, particularly in individuals of African ancestry 3

Antiretroviral therapy can be associated with various complications, including metabolic abnormalities, hypersensitivity reactions, mitochondrial toxicity, tenofovir-associated proximal tubulopathy, and CNS toxicity 6
The CNS Penetration Effectiveness (CPE) ranking system classifies antiretroviral drugs as having low, intermediate, or high CNS penetration based on physicochemical characteristics, measured CSF concentrations, and demonstrated effectiveness in the CNS 2
Elevated viral loads in the CSF predict subsequent neurocognitive impairments 2
Prolonged HAART usage combined with aging may increase amyloid deposition in the brain, potentially contributing to cognitive decline 2
Some antiretrovirals, particularly efavirenz, can cause direct CNS toxicity with neuropsychiatric symptoms 2
Patients with pre-existing cognitive impairment or neurological symptoms may benefit from regimens with moderate (not necessarily high) CNS penetration, and avoiding known neurotoxic agents is particularly important in older patients or those with existing neurocognitive concerns 2
Some clinical data suggests that CNS effectiveness of antiretroviral regimens can be improved by using CSF-penetrating drugs in patients with cognitive impairments 2